SG11201404850SA - IL-1β NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES - Google Patents

IL-1β NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES

Info

Publication number
SG11201404850SA
SG11201404850SA SG11201404850SA SG11201404850SA SG11201404850SA SG 11201404850S A SG11201404850S A SG 11201404850SA SG 11201404850S A SG11201404850S A SG 11201404850SA SG 11201404850S A SG11201404850S A SG 11201404850SA SG 11201404850S A SG11201404850S A SG 11201404850SA
Authority
SG
Singapore
Prior art keywords
monoclonal antibodies
human monoclonal
neutralizing human
neutralizing
antibodies
Prior art date
Application number
SG11201404850SA
Other languages
English (en)
Inventor
Cheng-I Wang
Angeline Goh
Siok Ping Yeo
Alessandra Mortellaro
Subhra Kumar Biswas
Florent Ginhoux
Pingyu Zhong
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Priority to SG11201404850SA priority Critical patent/SG11201404850SA/en
Publication of SG11201404850SA publication Critical patent/SG11201404850SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11201404850SA 2012-02-13 2013-02-13 IL-1β NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES SG11201404850SA (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SG11201404850SA SG11201404850SA (en) 2012-02-13 2013-02-13 IL-1β NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG2012010070 2012-02-13
PCT/SG2013/000057 WO2013122544A2 (fr) 2012-02-13 2013-02-13 Anticorps monoclonaux humains neutralisant il-1β
SG11201404850SA SG11201404850SA (en) 2012-02-13 2013-02-13 IL-1β NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES

Publications (1)

Publication Number Publication Date
SG11201404850SA true SG11201404850SA (en) 2014-09-26

Family

ID=54261183

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201404850SA SG11201404850SA (en) 2012-02-13 2013-02-13 IL-1β NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES
SG10201708562VA SG10201708562VA (en) 2012-02-13 2013-02-13 IL-1β Neutralizing Human Monoclonal Antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201708562VA SG10201708562VA (en) 2012-02-13 2013-02-13 IL-1β Neutralizing Human Monoclonal Antibodies

Country Status (16)

Country Link
US (5) US10167335B2 (fr)
EP (2) EP3736289A1 (fr)
JP (1) JP6383665B2 (fr)
CN (1) CN105431452B (fr)
CY (1) CY1123519T1 (fr)
DK (1) DK2814843T3 (fr)
ES (1) ES2798110T3 (fr)
HR (1) HRP20200964T1 (fr)
HU (1) HUE049860T2 (fr)
LT (1) LT2814843T (fr)
PL (1) PL2814843T3 (fr)
PT (1) PT2814843T (fr)
RS (1) RS60583B1 (fr)
SG (2) SG11201404850SA (fr)
SI (1) SI2814843T1 (fr)
WO (1) WO2013122544A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2814843T3 (da) 2012-02-13 2020-06-22 Agency Science Tech & Res IL-ß-NEUTRALISERENDE HUMANE MONOKLONALE ANTISTOFFER
CN106928354B (zh) * 2017-04-25 2020-07-17 长春金赛药业有限责任公司 抗IL-1β单克隆抗体及其应用
US20190048072A1 (en) * 2017-06-22 2019-02-14 Novartis Ag USE OF IL-1beta BINDING ANTIBODIES
CN117343173A (zh) * 2019-03-07 2024-01-05 瑞阳(苏州)生物科技有限公司 人IL-1β蛋白结合分子及其编码基因和应用
KR102087743B1 (ko) * 2019-06-10 2020-03-12 을지대학교 산학협력단 IL-1beta에 특이적으로 결합하는 항체 및 그의 용도

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EE03451B1 (et) 1994-07-05 2001-06-15 Steeno Research Group A/S Immunomodulaatorid
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US20030007972A1 (en) 1999-02-24 2003-01-09 Edward Tobinick Cytokine antagonists and other biologics for the treatment of bone metastases
GB0001448D0 (en) 2000-01-21 2000-03-08 Novartis Ag Organic compounds
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
WO2002020565A2 (fr) 2000-09-08 2002-03-14 Universität Zürich Groupes de proteines a domaines de repetition comprenant des modules de repetition
EP1590369B1 (fr) 2003-01-24 2016-03-16 Applied Molecular Evolution, Inc. Antagonistes de l'il-1 beta humaine
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
EP1641818B1 (fr) 2003-07-04 2008-12-03 Affibody AB Polypeptides presentant une affinite de liaison pour le recepteur 2 du facteur de croissance epidermique humain (her2)
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
EP1711196A4 (fr) 2003-12-05 2011-09-14 Bristol Myers Squibb Co Inhibiteurs des recepteurs du facteur de croissance endothelial vasculaire de type 2
CA2590164A1 (fr) 2005-01-26 2006-08-03 Amgen Fremont Inc. Anticorps diriges contre interleukine-1 beta
SI1899378T1 (sl) 2005-06-21 2010-02-26 Xoma Technology Ltd IL-1Beta vezavna protitelesa in njihovi fragmenti
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
EP1958957A1 (fr) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprenant un partie caractéristique des protéines appellées "Knottins"
JP2013507929A (ja) 2009-10-15 2013-03-07 アボット・ラボラトリーズ Ｉｌ−１結合蛋白質
WO2012121679A1 (fr) 2011-03-09 2012-09-13 Agency For Science, Technology And Research Méthode de modulation du phénotype d'un monocyte ou macrophage associé à un carcinome à cellules rénales
TWI743461B (zh) 2011-03-28 2021-10-21 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
DK2814843T3 (da) 2012-02-13 2020-06-22 Agency Science Tech & Res IL-ß-NEUTRALISERENDE HUMANE MONOKLONALE ANTISTOFFER
WO2016008851A1 (fr) 2014-07-14 2016-01-21 Boehringer Ingelheim International Gmbh Anticorps anti-il-1b
WO2016183176A1 (fr) 2015-05-12 2016-11-17 Drexel University Composés et compositions utiles pour traiter ou prévenir les métastases cancéreuses, et procédés dans lesquels ils sont employés
EP4378957A2 (fr) 2015-07-29 2024-06-05 Novartis AG Traitements combinés comprenant des molécules d'anticorps qui se lient à pd-1
US10397741B2 (en) 2016-11-11 2019-08-27 Shoreline Tracking Systems, LLC System and method for service tracking
WO2018235056A1 (fr) 2017-06-22 2018-12-27 Novartis Ag Anticorps se liant à il-1beta destinés à être utilisés dans le traitement du cancer
US20190048072A1 (en) 2017-06-22 2019-02-14 Novartis Ag USE OF IL-1beta BINDING ANTIBODIES
WO2020039401A1 (fr) 2018-08-24 2020-02-27 Novartis Ag Traitement comprenant des anticorps se liant à il-1 βeta et ses combinaisons

Also Published As

Publication number Publication date
SG10201708562VA (en) 2017-12-28
CN105431452B (zh) 2019-12-31
US20210155686A1 (en) 2021-05-27
CY1123519T1 (el) 2022-03-24
PL2814843T3 (pl) 2020-11-16
ES2798110T3 (es) 2020-12-09
US20190144535A1 (en) 2019-05-16
SI2814843T1 (sl) 2020-11-30
WO2013122544A2 (fr) 2013-08-22
DK2814843T3 (da) 2020-06-22
EP2814843B1 (fr) 2020-03-18
HRP20200964T1 (hr) 2020-10-30
EP2814843A4 (fr) 2016-04-06
PT2814843T (pt) 2020-06-18
WO2013122544A3 (fr) 2015-03-26
US11780913B2 (en) 2023-10-10
US10919962B2 (en) 2021-02-16
JP2015518368A (ja) 2015-07-02
RS60583B1 (sr) 2020-08-31
HUE049860T2 (hu) 2020-11-30
US20210024627A1 (en) 2021-01-28
WO2013122544A9 (fr) 2014-10-02
JP6383665B2 (ja) 2018-08-29
US20150037248A1 (en) 2015-02-05
EP3736289A1 (fr) 2020-11-11
US11912761B2 (en) 2024-02-27
EP2814843A2 (fr) 2014-12-24
LT2814843T (lt) 2020-09-25
US11702471B2 (en) 2023-07-18
US20210155685A1 (en) 2021-05-27
CN105431452A (zh) 2016-03-23
US10167335B2 (en) 2019-01-01

Similar Documents

Publication Publication Date Title
PL3088517T3 (pl) Ludzkie neutralizujące przeciwciało monoklonalne anty-il 33
HK1205144A1 (en) Bispecific chimeric antigen receptors and therapeutic uses thereof
HK1206040A1 (en) Anti-egfr antibodies and uses thereof egfr
HK1202563A1 (en) Sequence symmetric modified igg4 bispecific antibodies igg4
HK1202565A1 (en) Sequence symmetric modified igg4 bispecific antibodies igg4
EP2922874A4 (fr) Anticorps bispécifiques
IL229254A0 (en) Therapeutic antibodies
ZA201407272B (en) Anti-baff-anti-il-17 bispecific antibodies
EP2830660A4 (fr) Anticorps et épitopes anti-sema4d
HK1219961A1 (zh) 人抗α型干擾素抗體
SG11201404850SA (en) IL-1β NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES
EP2650367A4 (fr) Anticorps monoclonal humain
PT3016977T (pt) Anticorpos humanos anti-il-32
EP2924117A4 (fr) Nouvel anticorps humain contre il-18
EP2881467A4 (fr) Anticorps monoclonal dirigé contre la protéine midkine d'origine humaine
HUE041625T2 (hu) Terápiás ellenanyagok